737799-50-7

Usage

Uses

Used in Pharmaceutical Industry:
(R)-5,5-Dimethyl-3-(pyridin-3-ylsulfonyl)-thiazolidine-4-carboxylic acid is used as a therapeutic agent for the treatment of type 2 diabetes. It functions by increasing the sensitivity of cells to insulin, which leads to improved glucose uptake and a reduction in blood sugar levels.
Used in Anti-inflammatory Applications:
(R)-5,5-Dimethyl-3-(pyridin-3-ylsulfonyl)-thiazolidine-4-carboxylic acid is used as an anti-inflammatory agent due to its potential to alleviate conditions characterized by chronic inflammation. The pyridin-3-ylsulfonyl group is thought to contribute to its enhanced anti-inflammatory properties.
Used in Organic Synthesis:
(R)-5,5-Dimethyl-3-(pyridin-3-ylsulfonyl)-thiazolidine-4-carboxylic acid serves as a building block in organic synthesis. It is utilized for the generation of novel thiazolidine carboxylic acid derivatives with improved pharmacological properties, which could lead to the development of new drugs with better efficacy and fewer side effects.

Upstream product

• 16133-25-8 Pyridine-3-sulfonyl chloride 
• 72778-00-8 (R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid 

Downstream Products

• 737799-51-8 N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-L-tyrosine isopropyl ester 

Relevant academic research and scientific papers

PREPARATION OF POLYMER CONJUGATES OF THERAPEUTIC, AGRICULTURAL, AND FOOD ADDITIVE COMPOUNDS

Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.

Multimeric VLA-4 antagonists comprising polymer moieties

Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS

Disclosed are compounds of the f ormula : and the pharmaceutically acceptable salts thereof wherein the variables A, n, R5, R21-R24 and Q are defined herein. These compounds bind VLA-4. Certain of these compound also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

STEROID SPARING AGENTS AND METHODS OF USING SAME

This invention relates generally to the use of a steroid sparing agent for the preparation of a medicament for the treatment of inflammatory bowel diseases (IBD), asthma, multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid sparing immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.